Albany, NY -- (SBWIRE) -- 12/14/2017 -- As per estimates by Transparency Market Research, the global dilated cardiomyopathy therapeutics market will be worth US$328.6 mn by the end of 2020 vis-à-vis revenue, expanding at a CAGR of 4.6% from 2014 to 2020.

Read Report Overview @https://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html

The Dilated Cardiomyopathy Therapeutics Market is segmented on the basis of expression system, Geography and region

The segment of angiotensin II receptor blockers led amongst other drug class segments in 2013. This was followed by the segment of beta blockers. The high acceptance of angiotensin II receptor blocks is attributed to their effective therapeutic action for the treatment of dilated cardiomyopathy.

Geography-wise, the report segments the global dilated cardiomyopathy therapeutics market into: North America, Asia Pacific, Europe, and Rest of the World. North America stood as the leading regional market in 2013 mainly due to high incidence of cardiac diseases. Asia Pacific is expected to take the lead in the upcoming years as changing lifestyle resulting in increasing incidence of cardiac diseases propels growth of dilated cardiomyopathy therapeutics market.

Efforts to Develop Specific Drugs for Dilated Cardiomyopathy Propels Growth

The alarming rise in the prevalence of congestive heart failure is one of the prominent growth drivers of the global dilated cardiomyopathy market. Dilated cardiomyopathy accounts for 30-40% of total number of congestive heart failures each year. As per statistics of the World Health Organization, 17.5 million deaths in 2013 were related to heart disorders. The increasing incidence of congestive heart diseases has created an urgent need for effective drugs and treatment, thereby benefitting the dilated cardiomyopathy therapeutics market.

Due to this, several companies have initiated to carry out clinical trials so as to develop drugs specifically for dilated cardiomyopathy. At present, there is not a single FDA approved drug specifically for dilated cardiomyopathy because of which treatment administered is the same as that for congestive heart failure. For example, Array BioPharma is carrying out phase II study for its drug ARRY-371797 for the treatment of dilated cardiomyopathy. In addition, in 2014, Celladon Corporation completed its phase II study of MYDICAR to be used for the treatment of dilated cardiomyopathy. Success of these clinical trials will positively influence the global dilated cardiomyopathy therapeutics market.

Studies reveal that angiotensin receptor blockers such as valsartan can reduce probability of hospitalization by 28%. These drugs have also been effective for patients of systolic heart disease by reduction of deaths by 37% and also for reduced frequency of hospitalization. These factors are furthering the expansion of the global dilated cardiomyopathy therapeutics market.

Request A Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2293

Summary of Table of Content

Introduction

Executive Summary

Global Dilated Cardiomyopathy Therapeutics Market Overview

Global Dilated Cardiomyopathy Therapeutics Market, by Drug Class

Pipeline Analysis of Global Dilated Cardiomyopathy Therapeutics Market

Global Dilated

Cardiomyopathy Therapeutics Market, by Geography

Recommendations

Company Profiles

Get Full Report@https://www.transparencymarketresearch.com

About Transparency Market Research
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com